Azaperone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Azaperone
Accession Number
DB11376
Type
Small Molecule
Groups
Investigational, Vet approved
Description

Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine. It is used mainly in pigs and elephants. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon. Use in horses is avoided as adverse reactions may occur.

Structure
Thumb
Synonyms
  • 1-(3-(4-Fluorobenzoyl)propyl)-4-(2-pyridyl)piperazine
  • 1-(4-Fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone
  • 4'-fluoro-4-(4-(2-Pyridyl)-1-piperazinyl)butyrophenone
  • Azaperon
  • Azaperona
  • Azaperonum
  • NSC 170976
  • Stresnil
External IDs
NSC-170976 / R 1929 / R-1929
Categories
UNII
19BV78AK7W
CAS number
1649-18-9
Weight
Average: 327.403
Monoisotopic: 327.174690503
Chemical Formula
C19H22FN3O
InChI Key
XTKDAFGWCDAMPY-UHFFFAOYSA-N
InChI
InChI=1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2
IUPAC Name
1-(4-fluorophenyl)-4-[4-(pyridin-2-yl)piperazin-1-yl]butan-1-one
SMILES
FC1=CC=C(C=C1)C(=O)CCCN1CCN(CC1)C1=CC=CC=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineAzaperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAzaperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineAzaperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAzaperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Azaperone.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Azaperone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Azaperone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Azaperone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Azaperone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Azaperone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Azaperone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Azaperone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Azaperone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Azaperone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Azaperone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Azaperone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Azaperone.Approved, Illicit, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Azaperone is combined with Amikacin.Approved, Investigational, Vet Approved
AmisulprideAzaperone may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Azaperone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Azaperone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Azaperone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Azaperone.Experimental
AmphetamineAzaperone may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Azaperone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Azaperone.Approved
AzelastineAzaperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Azaperone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Azaperone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Azaperone is combined with Benperidol.Approved, Investigational
BenzphetamineAzaperone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Azaperone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Azaperone.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azaperone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Azaperone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azaperone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Azaperone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Azaperone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Azaperone.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Azaperone.Approved, Investigational
BuprenorphineAzaperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Azaperone is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Azaperone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Azaperone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Azaperone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Azaperone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Azaperone.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Azaperone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azaperone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Azaperone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Azaperone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Azaperone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Azaperone.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Azaperone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Azaperone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Azaperone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Azaperone.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Azaperone.Approved, Illicit, Investigational
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Azaperone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Azaperone.Approved
ChlorphentermineAzaperone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azaperone.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azaperone.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Azaperone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Azaperone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Azaperone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Azaperone.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Azaperone.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Azaperone is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Azaperone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Azaperone.Investigational
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Azaperone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Azaperone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Azaperone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azaperone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Azaperone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Azaperone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Azaperone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Azaperone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Azaperone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azaperone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Azaperone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Azaperone.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azaperone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Azaperone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Azaperone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Azaperone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Azaperone.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Azaperone.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Azaperone is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Azaperone is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azaperone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azaperone.Approved, Vet Approved
DextroamphetamineAzaperone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Azaperone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Azaperone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azaperone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Azaperone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Azaperone.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Azaperone is combined with Diethyl ether.Experimental
DiethylpropionAzaperone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Azaperone.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azaperone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Azaperone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azaperone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azaperone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Azaperone.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Azaperone.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azaperone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Azaperone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Azaperone is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Azaperone is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Azaperone.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Azaperone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Azaperone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Azaperone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Azaperone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Azaperone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Azaperone.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Azaperone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Azaperone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Azaperone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Azaperone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Eperisone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Azaperone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azaperone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Azaperone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Azaperone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Azaperone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Azaperone.Approved, Investigational
EthanolAzaperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Azaperone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Azaperone.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azaperone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Azaperone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Azaperone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azaperone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Azaperone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Azaperone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Azaperone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Azaperone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Azaperone.Illicit, Vet Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Azaperone.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Azaperone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azaperone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Azaperone.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Azaperone.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Azaperone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Azaperone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Azaperone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azaperone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azaperone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Azaperone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Azaperone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Azaperone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluvoxamine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Azaperone.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Azaperone.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Azaperone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Azaperone.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Azaperone.Approved, Illicit, Investigational
GepefrineAzaperone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Azaperone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Azaperone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azaperone.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Azaperone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Azaperone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Azaperone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Azaperone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Azaperone.Approved
HydrocodoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azaperone.Approved, Illicit
HydroxyamphetamineAzaperone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Azaperone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Azaperone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Azaperone is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Azaperone is combined with Indiplon.Investigational
Iofetamine I-123Azaperone may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Azaperone can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Azaperone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Azaperone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Azaperone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azaperone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Azaperone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Azaperone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Azaperone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Azaperone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Azaperone.Approved
LevodopaThe therapeutic efficacy of Azaperone can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azaperone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Azaperone is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azaperone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Azaperone.Approved, Investigational
LisdexamfetamineAzaperone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Azaperone.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Azaperone.Illicit
LofexidineThe therapeutic efficacy of Azaperone can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Azaperone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Azaperone.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Azaperone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Azaperone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Azaperone is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Azaperone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Azaperone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Azaperone.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Azaperone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Azaperone.Approved
MedazepamThe risk or severity of adverse effects can be increased when Azaperone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Azaperone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Azaperone.Approved, Investigational
MephedroneAzaperone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAzaperone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azaperone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azaperone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Azaperone is combined with Meptazinol.Experimental
MequitazineAzaperone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azaperone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Azaperone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Azaperone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Azaperone.Approved, Illicit
MethamphetamineAzaperone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Azaperone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Azaperone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Azaperone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Azaperone.Approved
MethotrimeprazineAzaperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Azaperone.Approved, Investigational, Vet Approved
MethoxyphenamineAzaperone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Azaperone.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Azaperone.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Azaperone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Azaperone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Azaperone.Approved, Investigational
MetyrosineAzaperone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Azaperone.Approved, Illicit
MidomafetamineAzaperone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Azaperone is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved, Investigational
MirtazapineAzaperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAAzaperone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Azaperone.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Azaperone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Azaperone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azaperone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Azaperone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Azaperone is combined with Neomycin.Approved, Vet Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Azaperone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Azaperone.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Azaperone is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Azaperone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Azaperone.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Azaperone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azaperone.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Azaperone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Azaperone.Approved, Illicit
OrphenadrineAzaperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Azaperone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Azaperone.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Azaperone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Azaperone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azaperone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azaperone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azaperone.Approved
ParaldehydeAzaperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Azaperone is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Azaperone is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Azaperone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Azaperone.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved
PerazineThe risk or severity of adverse effects can be increased when Azaperone is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Azaperone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Azaperone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Azaperone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Azaperone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Azaperone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Azaperone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Azaperone.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Azaperone.Approved
PhentermineAzaperone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Azaperone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Azaperone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azaperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Azaperone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Azaperone is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Azaperone.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Azaperone is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Azaperone.Approved
PramipexoleAzaperone may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Azaperone.Approved, Illicit
PregabalinThe therapeutic efficacy of Azaperone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Azaperone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Azaperone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Azaperone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Azaperone.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Azaperone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Azaperone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Azaperone.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Azaperone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Azaperone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Azaperone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Azaperone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Azaperone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Azaperone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Azaperone.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Azaperone.Approved
PyrantelThe risk or severity of adverse effects can be increased when Azaperone is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Azaperone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azaperone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Azaperone.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Azaperone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Azaperone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Azaperone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Azaperone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azaperone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azaperone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Azaperone.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Azaperone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Azaperone is combined with Ritanserin.Investigational
RitobegronAzaperone may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Azaperone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Romifidine.Vet Approved
RopiniroleAzaperone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Azaperone.Approved
RotigotineAzaperone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Azaperone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Azaperone.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Azaperone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Azaperone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Azaperone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Azaperone.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Azaperone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azaperone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Azaperone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone.Approved, Investigational
SulpirideAzaperone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Azaperone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Azaperone.Approved, Investigational
SuvorexantAzaperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Azaperone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Azaperone.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Azaperone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Azaperone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Azaperone.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Azaperone.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Azaperone is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Azaperone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Azaperone.Investigational
ThalidomideAzaperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azaperone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Azaperone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Azaperone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azaperone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Azaperone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Azaperone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Azaperone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azaperone.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Azaperone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Azaperone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Azaperone.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azaperone.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Azaperone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Azaperone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Azaperone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Azaperone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azaperone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Azaperone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azaperone.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Azaperone is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Azaperone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Azaperone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Azaperone.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Azaperone is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Azaperone is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Azaperone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Azaperone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Azaperone is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Azaperone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Azaperone.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Azaperone is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Azaperone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Azaperone.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Azaperone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Azaperone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Azaperone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Azaperone.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Azaperone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Azaperone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Azaperone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Azaperone.Approved, Investigational
ZolpidemAzaperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Azaperone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Azaperone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Azaperone.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azaperone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Baeyens W, De Moerloose P, De Taeye L: Fluorescence characteristics of azaperone and of an azaperone mononitrogen oxide. J Pharm Sci. 1977 Dec;66(12):1787-9. [PubMed:925952]
  2. Gerbig T: [Azaperone (Stresnil) as a sedative for dogs]. Berl Munch Tierarztl Wochenschr. 1979 Jan 1;92(1):12-5. [PubMed:420685]
  3. Borka L, Valdimarsdottir S: The polymorphism of azaperone and clotrimazole. Acta Pharm Suec. 1975;12(5-6):479-84. [PubMed:1217501]
  4. Lang E: [Use of azaperone on the pig]. Berl Munch Tierarztl Wochenschr. 1970 Apr 15;83(8):141-3. [PubMed:5519354]
  5. Allsup FC, Hillidge CJ, Lees P, Serrano L: Azaperone-metomidate anaesthesia in the horse. Vet Rec. 1973 Nov 3;93(18):498. [PubMed:4786114]
  6. Olson ME, Renchko P: Azaperone and azaperone-ketamine as a neuroleptic sedative and anesthetic in rats and mice. Lab Anim Sci. 1988 Jun;38(3):299-304. [PubMed:3411917]
  7. Heinonen ML, Raekallio MR, Oliviero C, Ahokas S, Peltoniemi OA: Comparison of azaperone-detomidine-butorphanol-ketamine and azaperone-tiletamine-zolazepam for anaesthesia in piglets. Vet Anaesth Analg. 2009 Mar;36(2):151-7. doi: 10.1111/j.1467-2995.2008.00443.x. [PubMed:19239653]
  8. Duverger-van Bogaert M, Vanparys P, de Meester C, Marsboom R: Mutagenicity evaluation of azaperone in the Salmonella/microsome test. Drug Chem Toxicol. 1987;10(3-4):329-38. [PubMed:3322780]
  9. Miller BF, Osborn DA, Lance WR, Howze MB, Warren RJ, Miller KV: Butorphanol-azaperone-medetomidine for immobilization of captive white-tailed deer. J Wildl Dis. 2009 Apr;45(2):457-67. [PubMed:19395755]
  10. Radcliffe RW, Ferrell ST, Childs SE: Butorphanol and azaperone as a safe alternative for repeated chemical restraint in captive white rhinoceros (Ceratotherium simum). J Zoo Wildl Med. 2000 Jun;31(2):196-200. [PubMed:10982132]
  11. Read MR, McCorkell RB: Use of azaperone and zuclopenthixol acetate to facilitate translocation of white-tailed deer (Odocoileus virginianus). J Zoo Wildl Med. 2002 Jun;33(2):163-5. [PubMed:12398308]
  12. Carmona JU, Giraldo CE, Aristizabal W, Garcia A, Vallejo LG: Evaluation of the effects of the sedation with azaperone/acepromazine and immobilization with guaiphenesin/thiopentone in mules. Vet Res Commun. 2007 Feb;31(2):125-32. Epub 2006 Dec 20. [PubMed:17186408]
  13. Cerkvenik-Flajs V: Determination of residues of azaperone in the kidneys by liquid chromatography with fluorescence detection. Anal Chim Acta. 2007 Mar 14;586(1-2):374-82. Epub 2006 Nov 10. [PubMed:17386737]
  14. Axiak SM, Jaggin N, Wenger S, Doherr MG, Schatzmann U: Anaesthesia for castration of piglets: comparison between intranasal and intramuscular application of ketamine, climazolam and azaperone. Schweiz Arch Tierheilkd. 2007 Sep;149(9):395-402. [PubMed:17929705]
  15. Wenger S, Boardman W, Buss P, Govender D, Foggin C: The cardiopulmonary effects of etorphine, azaperone, detomidine, and butorphanol in field-anesthetized white rhinoceroses (Ceratotherium simum). J Zoo Wildl Med. 2007 Sep;38(3):380-7. [PubMed:17939346]
  16. Wolfe LL, Goshorn CT, Baruch-Mordo S: Immobilization of black bears (Ursus americanus) with a combination of butorphanol, azaperone, and medetomidine. J Wildl Dis. 2008 Jul;44(3):748-52. [PubMed:18689666]
  17. Mich PM, Wolfe LL, Sirochman TM, Sirochman MA, Davis TR, Lance WR, Miller MW: Evaluation of intramuscular butorphanol, azaperone, and medetomidine and nasal oxygen insufflation for the chemical immobilization of white-tailed deer, Odocoileus virginianus. J Zoo Wildl Med. 2008 Sep;39(3):480-7. [PubMed:18817017]
  18. Aoki Y, Hakamata H, Igarashi Y, Uchida K, Kobayashi H, Hirayama N, Kotani A, Kusu F: Simultaneous determination of azaperone and azaperol in animal tissues by HPLC with confirmation by electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):166-72. doi: 10.1016/j.jchromb.2008.11.047. Epub 2008 Dec 7. [PubMed:19111512]
  19. Siegal-Willott J, Citino SB, Wade S, Elder L, Hayek LA, Lance WR: Butorphanol, azaperone, and medetomidine anesthesia in free-ranging white-tailed deer (Odocoileus virginianus) using radiotransmitter darts. J Wildl Dis. 2009 Apr;45(2):468-80. [PubMed:19395756]
  20. Zawadzka I, Rodziewicz L: [Determination of azaperone and carazolol residues in animals kidney using LC-MS/MS method]. Rocz Panstw Zakl Hig. 2009;60(1):19-23. [PubMed:19579764]
  21. Mentaberre G, Lopez-Olvera JR, Casas-Diaz E, Bach-Raich E, Marco I, Lavin S: Use of haloperidol and azaperone for stress control in roe deer (Capreolus capreolus) captured by means of drive-nets. Res Vet Sci. 2010 Jun;88(3):531-5. doi: 10.1016/j.rvsc.2009.11.001. Epub 2009 Dec 14. [PubMed:20006891]
  22. Nussbaumer I, Indermuhle N, Zimmermann W, Leist Y: [Piglet castration using injection anesthesia: experiences with a combination of azaperone, butorphanol and ketamine]. Schweiz Arch Tierheilkd. 2011 Jan;153(1):33-5. doi: 10.1024/0036-7281/a000140. [PubMed:21210371]
  23. Ruediger K, Schulze M: Post-farrowing stress management in sows by administration of azaperone: effects on piglets performance. J Anim Sci. 2012 Jul;90(7):2331-6. doi: 10.2527/jas.2011-4661. Epub 2012 Jan 27. [PubMed:22287670]
  24. McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC: Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry. 2013 Mar 1;73(5):464-71. doi: 10.1016/j.biopsych.2012.08.027. Epub 2012 Nov 7. [PubMed:23140663]
  25. Lahrmann KH, Baars J, Rintisch U: [Perioperative intensive-medical investigations regarding compatibility of the ketamine-azaperone-general anesthesia in pigs]. Berl Munch Tierarztl Wochenschr. 2014 Jan-Feb;127(1-2):3-11. [PubMed:24490337]
  26. Bapodra P, Cracknell J, Wolfe BA: Comparison of butorphanol-detomidine versus butorphanol-azaperone for the standing sedation of captive greater one-horned rhinoceroses (Rhinoceros unicornis). J Zoo Wildl Med. 2014 Mar;45(1):60-8. [PubMed:24712163]
  27. Wolfe LL, Fisher MC, Davis TR, Miller MW: Efficacy of a low-dosage combination of butorphanol, azaperone, and medetomidine (BAM) to immobilize Rocky Mountain elk. J Wildl Dis. 2014 Jul;50(3):676-80. doi: 10.7589/2014-02-026. Epub 2014 May 7. [PubMed:24807358]
  28. Boardman WS, Caraguel CG, Raath JP, Van Zijll Langhout M: Intravenous butorphanol improves cardiopulmonary parameters in game-ranched white rhinoceroses (Ceratotherium simum) immobilized with etorphine and azaperone. J Wildl Dis. 2014 Oct;50(4):849-57. doi: 10.7589/2013-12-327. Epub 2014 Aug 8. [PubMed:25105814]
  29. Szabo Z, Venter DJ, Luyt Edu C, Raath C: The use of thiafentanil oxalate and azaperone for reversible immobilisation of African buffalo (Syncerus caffer) within a nature reserve - Short communication. Acta Vet Hung. 2015 Mar;63(1):11-5. doi: 10.1556/AVet.2015.002. [PubMed:25655411]
  30. Lapid R, Shilo-Benjamini Y: IMMOBILIZATION OF CAPTIVE NUBIAN IBEX (CAPRA NUBIANA) WITH BUTORPHANOL-MIDAZOLAM-MEDETOMIDINE OR BUTORPHANOL-AZAPERONE-MEDETOMIDINE AND ATIPAMEZOLE REVERSAL. J Zoo Wildl Med. 2015 Jun;46(2):291-7. doi: 10.1638/2014-0202R1.1. [PubMed:26056882]
  31. Serrano L, Lees P: The applied pharmacology of azaperone in ponies. Res Vet Sci. 1976 May;20(3):316-23. [PubMed:935668]
External Links
KEGG Drug
D02620
ChemSpider
14695
BindingDB
50036733
ChEBI
88301
ChEMBL
CHEMBL340211
Wikipedia
Azaperone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentFeeling Anxious1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.23 mg/mLALOGPS
logP2.73ALOGPS
logP3.21ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)16.4ChemAxon
pKa (Strongest Basic)7.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.44 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity94.27 m3·mol-1ChemAxon
Polarizability36.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-3900000000-2b80dd893322c22b1ec2

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Pyridinylpiperazines / N-arylpiperazines / Phenylbutylamines / Butyrophenones / Aryl alkyl ketones / Dialkylarylamines / Benzoyl derivatives / Aminopyridines and derivatives / N-alkylpiperazines / Fluorobenzenes
show 10 more
Substituents
Alkyl-phenylketone / Pyridinylpiperazine / N-arylpiperazine / Butyrophenone / Phenylbutylamine / Benzoyl / Dialkylarylamine / Aryl alkyl ketone / Aminopyridine / Fluorobenzene
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:15 / Updated on August 02, 2018 06:23